Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum AB    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB

(SOBI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
159.35(c) 155.8(c) 157.8(c) 159.25(c) 160(c) Last
1 047 263 1 042 942 898 855 930 192 544 492 Volume
-2.89% -2.23% +1.28% +0.92% +0.47% Change
More quotes
Financials
Sales 2020 15 363 M 1 832 M 1 832 M
Net income 2020 2 795 M 333 M 333 M
Net Debt 2020 11 138 M 1 328 M 1 328 M
P/E ratio 2020 17,0x
Yield 2020 -
Sales 2021 16 345 M 1 949 M 1 949 M
Net income 2021 3 166 M 377 M 377 M
Net Debt 2021 6 319 M 753 M 753 M
P/E ratio 2021 15,0x
Yield 2021 -
Capitalization 47 183 M 5 635 M 5 625 M
EV / Sales 2020 3,80x
EV / Sales 2021 3,27x
Nbr of Employees 1 471
Free-Float 61,3%
More Financials
Company
Swedish Orphan Biovitrum AB is specialized in the development, manufacturing and marketing of therapeutic products intended for the treatment of rare diseases (hemophilia, inflammatory and autoimmune illnesses, hereditary metabolic diseases, etc.). The turnover per source of income can be broken down as follows: - sales of products (87.3%); - royalties (9.6%); - sales of sub-contracted manufactured products... 
More about the company
Notations Surperformance© of Swedish Orphan Biovitrum AB
Trading Rating : Investor Rating :
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB
2020FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Rece..
GL
2020SWEDISH ORPHAN BIOVITRUM : Sobi appoints new Head of North America ahead of laun..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Doptelet receives positive opinion from CHMP for trea..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Realising opportunities for future growth and financi..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Emapalumab submission in China for primary HLH
AQ
2020SWEDISH ORPHAN BIOVITRUM : Doptelet® (avatrombopag) receives positive opinion fr..
AQ
2020Apellis Pharmaceuticals, Sobi Late-Stage Study of Pegcetacoplan Shows Improve..
MT
2020SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis report positive top-line results at ..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Emapalumab submission in China for primary HLH
AQ
2020REALISING OPPORTUNITIES FOR FUTURE G : Sobi Capital Markets Day 2020
AQ
2020SWEDISH ORPHAN BIOVITRUM : Agenda, Sobi Capital Markets Day 2020
AQ
2020AGENDA : Sobi Capital Markets Day 2020
AQ
2020Apellis Pharmaceuticals, Swedish Orphan Dose First Patient in Study of Amyotr..
MT
2020SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis announce first patient dosed in pote..
AQ
2020SWEDISH ORPHAN BIOVITRUM : CHMP has adopted a negative opinion for emapalumab in..
AQ
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB
2020SWEDISH ORPHAN BIOVITRUM AB : chute après son étude sur l’Avatrombopag
2020AVIS D'ANALYSTES DU JOUR : Altice, AXA, Givaudan, Ipsen, Logitech, Proximus, Som..
2020AVIS D'ANALYSTES DU JOUR : BNP Paribas, Boiron, Givaudan, Heineken, Swedish Orph..
2020SWEDISH ORPHAN BIOVITRUM : publication des résultats semestriels
2020SWEDISH ORPHAN BIOVITRUM : Veröffentlichung des Halbjahresergebnisses
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB
Duration : Period :
Swedish Orphan Biovitrum AB Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 214,50 SEK
Last Close Price 160,00 SEK
Spread / Highest target 62,5%
Spread / Average Target 34,1%
Spread / Lowest Target 9,38%
EPS Revisions
Managers and Directors
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Henrik Stenqvist Chief Financial Officer
Anne Marie de Jonge Schuermans Head-Technical Operations
Ravi M. Rao Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM AB-3.67%5 635
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993